| Date Filed | Type | Description |
| 04/08/2021 |
GN
| Mereo BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference |
| 03/31/2021 |
GN
| Mereo BioPharma Reports Full Year 2020 Financial Results and Recent Highlights |
| 02/18/2021 |
GN
| Mereo BioPharma to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference |
| 02/12/2021 |
GN
| Mereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares |
| 02/10/2021 |
GN
| Mereo BioPharma Group plc Announces Pricing of Public Offering of American Depositary Shares |
| 12/15/2020 |
GN
| Mereo BioPharma Provides Update on AIM Delisting and Continued Listing of its ADSs on Nasdaq, and Provides Update on agreements with Silicon Valley Bank and Kreos Capital |
| 11/23/2020 |
GN
| Mereo BioPharma Appoints Suba Krishnan, M.D. as Senior Vice President of Clinical Development |
| 11/16/2020 |
GN
| Mereo BioPharma to Hold Virtual R&D Day on Tuesday, November 24, 2020 |
| 11/10/2020 |
GN
| Mereo BioPharma to Present at the Stifel 2020 Virtual Healthcare Conference |
| 10/19/2020 |
GN
| Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT) |
| 09/24/2020 |
GN
| Mereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta |
| 08/25/2020 |
GN
| Mereo BioPharma Announces Initiation of Placebo-Controlled Phase 1b/2 Clinical Trial with Alvelestat in COVID-19 Respiratory Disease |
| 06/30/2020 |
GN
| Mereo BioPharma Strengthens Management Team; Appoints John Lewicki, PhD, as Chief Scientific Officer and Ann Kapoun, PhD, as SVP of Translational Research and Development |
| 06/16/2020 |
GN
| Mereo BioPharma Announces Financial Results for the Year Ended December 31, 2019 |
| 06/04/2020 |
GN
| Mereo BioPharma Announces Completion of $70 Million Private Placement |
| 03/27/2020 |
GN
| Business Update and Directorate Change |
| 02/19/2020 |
GN
| Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor |
| 01/14/2020 |
GN
| Mereo BioPharma Announces Additional Positive Data from Phase 2b ASTEROID Study of Setrusumab in Adults with Osteogenesis Imperfecta and Provides Update on Regulatory Progress |
| 01/13/2020 |
GN
| Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab |
| 11/11/2019 |
GN
| Mereo BioPharma's Setrusumab Demonstrates Dose-Dependent Bone Building and Trend in Fracture Reduction in Phase 2b ASTEROID Study in Adults with Osteogenesis Imperfecta |
| 09/17/2019 |
GN
| Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2019 and Provides Corporate Update |
| 07/16/2019 |
GN
| Mereo BioPharma Appoints Richard Francis as Head of Pharmaceutical Development |
| 05/30/2019 |
GN
| Mereo BioPharma Group plc Announces Positive Early 6 Month Data from the Open Label Arm of the Phase 2b Clinical Study in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with the Anti-Sclerostin Antibody, BPS-804 (setrusumab) |
| 05/03/2019 |
GN
| Mereo BioPharma Group plc (“Mereo” or the “Company” or the “Group”) Intention to Purchase Shares by Trustee of Employee Benefit Trust |
| 04/29/2019 |
GN
| Mereo BioPharma Group Plc ("Mereo" or the "Company" or the "Group") Preliminary Results for the Year Ended December 31, 2018 -- Strong Operational Progress |
| 04/26/2019 |
GN
| Mereo Biopharma to Announce Preliminary Results for the Full Year 2018 and Host Conference Call on April 29, 2019 |
| 04/24/2019 |
GN
| Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Admission to trading on AIM of New Shares and initiation of trading on Nasdaq of American Depositary Shares |
| 10/24/2012 |
8-K
| Quarterly results |
| 03/30/2012 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| 01/17/2012 |
8-K
| Form 8-K - Current report |
| 12/22/2011 |
10-Q
| Quarterly Report for the period ended September 30, 2011 |
| 12/13/2011 |
4
| FOSSEEN DWAYNE (CEO) has filed a Form 4 on MIRENCO INC|
Txns:
| Sold 4,500 shares
@ $0.35, valued at
$1.6k
|
|
| 09/06/2011 |
4
| WILLIAMS DONALD D (Director) has filed a Form 4 on MIRENCO INC|
Txns:
| Bought 1,000 options
@ $0.07, valued at
$70 |
|
| 09/06/2011 |
4
| FOSSEEN DWAYNE (Director) has filed a Form 4 on MIRENCO INC|
Txns:
| Bought 1,000 options
@ $0.07, valued at
$70 |
|
|